Menu
Menu
Divis Laboratories Ltd has seen impressive growth, with its stock rising 61.58% over the past year, significantly outperforming both the Nifty and Nifty Pharma indices. This blog explores the key factors driving Divis' strong performance, including its consistent gains, solid fundamentals, and market outlook
Marksans Pharma saw a 1.94% increase in its stock after receiving USFDA approval for its generic Loratadine Tablets. This approval opens new opportunities in the allergy relief market, complementing the company’s strong financial performance with a 15.8% rise in net profit for Q2 FY25.
Tata Chemicals is set to invest Rs 655 crore in a new pharmaceutical-grade sodium bicarbonate plant in Northwich, UK. The facility will triple production capacity, enhancing TCEL's ability to meet growing global demand in the pharmaceutical sector.
Orchid Pharma delivered strong financial results for Q2 FY24, reporting a 37.58% increase in net profit and a 12.04% rise in sales. The company’s improved operating margins and robust demand for its pharmaceutical products have contributed to its growth. Learn more about Orchid Pharma’s performance and future prospects in this detailed analysis.
n a significant move, Torrent Pharmaceuticals' promoter has sold a 2.92% stake for approximately Rs 3,086.4 crore, raising questions about market impact and strategic intent. This comes alongside a strong quarterly performance, with a 17% increase in net profit and a robust revenue growth of 8.6%. Join us as we delve into the details of the stake sale, analyze recent financial results, and explore what the future holds for Torrent Pharma.
Torrent Pharmaceuticals recently saw its promoter offload a 2.92% stake, raising over Rs 3,000 crore. Despite this significant transaction, the company reported strong Q2 results, with a 17% rise in net profit. Dive into our analysis of market reactions, analyst ratings, and what this means for the future of Torrent Pharma.
Alembic Pharmaceuticals has secured USFDA approval for its Diltiazem Hydrochloride Extended-Release Capsules, a significant addition to its portfolio for hypertension treatment. With an estimated market size of $28.2 million, this approval not only enhances Alembic's standing in the pharmaceutical sector but also reflects its ongoing commitment to developing effective healthcare solutions. In this blog, we explore the implications of this approval, recent financial performance, and what it means for patients and investors alike.
Strides Pharma’s OneSource Specialty Pharma Ltd. has successfully secured ₹801 crore in investment commitments from prominent investors ahead of its upcoming listing. This funding positions OneSource for accelerated growth and unlocks significant value for shareholders, with an impressive pre-money valuation reflecting strong market confidence in the company's strategic vision. Explore the implications of this investment and what it means for the future of Strides Pharma.
Akums Drugs and Pharmaceuticals has entered a licensing agreement with Canadian firm Triple Hair Inc., securing exclusive rights to develop and market innovative hair care products in India. This strategic move not only diversifies Akums' portfolio but also aims to meet the rising consumer demand for quality personal care solutions. Explore the potential impact of this collaboration on the Indian market and what it means for consumers.
Introduction: Zydus Lifesciences Ltd has accomplished a significant milestone with the final approval from the United States Food and Drug Administration (USFDA) for its typical model of Paliperidone prolonged-release capsules, […]